Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px

Deals > All

Total search results: 10200 | Ordered by Date (descending)
1 2 3 ... 101 102 103  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Evox Therapeutics–FTI Consulting: public relations, 202003 service existent by FTI Consulting 2020-03-26
SutroVax–Abingworth: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Abingworth 2020-03-26
SutroVax–Medicxi: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Medicxi 2020-03-26
SutroVax–Roche: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Roche Venture Fund 2020-03-26
SutroVax–SEVERAL: investment, 202003 financing round Series D $110m co-led by new investors RA Capital + Janus Henderson 2020-03-26
Takeda–Evox Therapeutics: exosome therapeutics, 202003– collab up to $926m + tiered royalties developm for up to 5 rare disease targets 2020-03-26
AstraZeneca–Silence Therapeutics: siRNA molecules, 202003– collab r+d strategic alliance $60m upfront + up to $400m for each disease target 2020-03-25
Roche–Forge Therapeutics: antibiotics, 202003– collab research + license option up to $190.5m for FG-LpxC LUNG program for lung infections 2020-03-25
Silence Therapeutics–AstraZeneca: investment, 202003 equity investment $20m in connection with strategic siRNA alliance 2020-03-25
Immunogenesis–Minapharm: biopharma production, 202003– supply €na cell line + process developm + production of I-O-candidate by ProBiogen AG 2020-03-24
Bayer–Curadev: STING agonists, 202003– collab research + license agreem incl upfront payment + €250m milestones + single-digit royalties 2020-03-23
DeepSee project–Germany (govt): grant, 202003– funding from BMWi (ZIM) + Enterprise Singapore for single cell analysis for cancer drug r+d 2020-03-23
DeepSee project–Proteona: single cell analysis, 202003– collab project partner AI-driven multi-omics single cell analysis for cancer drug r+d 2020-03-23
DeepSee project–Singapore (govt): grant, 202003– funding from Enterprise Singapore + German BMWi for single cell analysis for cancer drug r+d 2020-03-23
DeepSee project–Synovo: single cell analysis, 202003– collab project partner AI-driven multi-omics single cell analysis for cancer drug r+d 2020-03-23
DeepSee project–Univ Tübingen: single cell analysis, 202003– collab NMI project partner AI-driven multi-omics single cell analysis for cancer drug r+d 2020-03-23
Koki Holdings–Eppendorf: investment, 202003– acquisition €na of Koki’s Centrifuge + Processing business by Eppendorf from KKR 2020-03-19
BMS–Oxford BioMedica: lentiviral vector technology, 202003– license non-excl + supply agreem LentiVector for CAR-T + TCR-T therapeutics of Juno 2020-03-18
OncoOne–SEVERAL: investment, 202003 financing round Series A €13m investors include FFG + AWS + two family offices 2020-03-18
OncoOne–Trophic Communications: public relations, 202003 service existent by Trophic Communications 2020-03-18
Immatics–Arya Sciences: investment, 202003 reverse merger resulting in Nasdaq-listing of Immatics + $148m cash held by Arya 2020-03-17
Immatics–SEVERAL: investment, 202003 common stock PIPE $104m led by Perceptive Advisors 2020-03-17
MolMed–Asahi Glass: investment, 202003– cash tender offer €240m for 463.5m shares at €0.518/share by AGC Inc ANNOUNCED 2020-03-17
Pfizer–BioNTech: mRNA-based vaccines, 202003– collab development of COVID-19 vaccine 2020-03-17
BioNTech–Fosun: investment, 202003 equity investment €44m for 1.58m ordinary shares by Fosun Pharma as part of COVID-19 vaccine collab 2020-03-16
Fosun–BioNTech: mRNA-based vaccines, 202003– collab up to €120m + profit sharing development of COVID-19 vaccine in China with Fosun Pharma 2020-03-16
Tempus Labs–Novo Group: investment, 202003 financing round Series G totalling $100m incl investor Novo Holdings 2020-03-13
Tempus Labs–SEVERAL: investment, 202003 financing round Series G $100m incl Baillie Gifford + Franklin Templeton + NEA + Novo Holdings + T Rowe Price 2020-03-13
Life Sciences Partners–BMS: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor BMS 2020-03-10
Life Sciences Partners–EU (govt): investment, 202003 final closing totalling €600m of LSP 6 fund incl investor EIF 2020-03-10
Life Sciences Partners–Otsuka: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor Otsuka Pharmaceutical 2020-03-10
Life Sciences Partners–SEVERAL: investment, 202003 final closing €600m of LSP 6 fund with investors incl BMS + Otsuka + EIF 2020-03-10
Calixar–SEVERAL: investment, 202003 second financing round €2.5m 2020-03-09
iAtros–Bavaria (govt): investment, 202003 seed financing round totalling €2m incl investor Bayern Kapital 2020-03-09
iAtros–High-Tech Gründerfonds: investment, 202003 seed financing round totalling €2m incl investor HTGF 2020-03-09
iAtros–OTHER: investment, 202003 seed financing round totalling €2m incl several business angels 2020-03-09
iAtros–SEVERAL: investment, 202003 seed financing round €2m from HTGF + Bayern Kapital + several business angels 2020-03-09
Numab–MacDougall Biomedical Communications: public relations, 202003 service existent by MacDougall 2020-03-09
Bone Therapeutics–Image Box: public relations, 202003– supply service by Image Box PR 2020-03-06
Autolus–MolMed: viral vectors, 202003– collab multi-year developm + supply of viral vectors by MolMed for T cell cancer therapies 2020-03-05
Biotalys–Novalis LifeSciences: investment, 202003 financing round Series C 2nd closing totalling €10m incl new investor Novalis LifeSciences 2020-03-05
Biotalys–SEVERAL: investment, 202003 financing round Series C €10m 2nd closing bringing total Series C to €45m 2020-03-05
AstraZeneca–Voluntis: digital therapeutics, 202003 collab existent 2020-03-04
BMS–Voluntis: digital therapeutics, 202003–collab developm of digital therapeutics using Theraxium Oncology platform 2020-03-03
Qiagen–Barclays: financial services, 202003 supply service Barclays Bank plc is financial advisor w regard to acquisition by Thermo Fisher 2020-03-03
Qiagen–De Brauw Blackstone Westbroek: legal services, 202003 supply service De Brauw BW NV is legal counsel w regard to acquisition by Thermo Fisher 2020-03-03
Qiagen–Goldman Sachs: financial services, 202003 supply service Goldman Sachs Intl is lead financial advisor w regard to acquisition by Thermo Fisher 2020-03-03
Qiagen–Linklaters: legal services, 202003 supply service Linklaters LLP is legal counsel w regard to acquisition by Thermo Fisher 2020-03-03
Qiagen–Mintz Levin Cohn: legal services, 202003 supply service Mintz Levin Cohn FGP is legal counsel w regard to acquisition by Thermo Fisher 2020-03-03
Qiagen–Thermo Fisher: investment, 202003– acquisition €9.14b cash tender offer at €39/share ANNOUNCED 2020-03-03
Thermo Fisher–JPMorgan Chase: financial services, 202003 supply service JP Morgan Securities LLC is financial advisor w regard to Qiagen acquisition 2020-03-03
Thermo Fisher–Morgan Stanley: financial services, 202003 supply service Morgan Stanley & Co LLC is financial advisor w regard to Qiagen acquisition 2020-03-03
Thermo Fisher–Wachtel Lipton Rosen & Katz: legal services, 202003 legal council to Thermo Fisher with regard to acquisition of Qiagen 2020-03-03
Agilent–Visiopharm: image analysis software, 202003– collab co-marketing of Visiopharm’s AI-driven solutions for digital pathology 2020-03-02
Evonetix–SEVERAL: investment, 202003 financing round Series B $30m (£23m) led by new investor Foresite Capital 2020-03-02
Immunocore–General Atlantic: investment, 202003 financing round Series B totalling $130m incl new + lead investor General Atlantic 2020-03-02
Immunocore–SEVERAL: investment, 202003 financing round Series B $130m led by new investor General Atlantic 2020-03-02
Sterling Pharma Solutions–Thermo Fisher: LC system, 202003 supply early customer for Vanquish Core HPLC System 2020-03-02
Boehringer–Trutino Biosciences: cancer immunotherapy, 202002– collab research + ww excl license to develop up to 3 candidates using ODC technology 2020-02-27
Centogene–Coulter Partners: recruitment services, 202002 supply service placement of Philip Lambert as CSO at Centogen based in US 2020-02-26
FinnGen–AbbVie: genomics, 202002 collab existent AbbVie is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–AstraZeneca: genomics, 202002 collab existent AstraZeneca is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Biogen: genomics, 202002 collab existent Biogen is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–BMS: genomics, 202002 collab existent BMS is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–GSK: genomics, 202002 collab existent GSK is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–JnJ: genomics, 202002– collab Janssen new industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Maze Therapeutics: genomics, 202002– collab Maze new industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Merck (US): genomics, 202002 collab existent MSD is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Pfizer: genomics, 202002 collab existent Pfizer is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Roche: genomics, 202002 collab existent Genentech is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Sanofi: genomics, 202002 collab existent Sanofi is industry partner of Finnish genome research project FinnGen 2020-02-25
ImmunOs Therapeutics–Minapharm: biopharma production, 202002– supply €na support developm using DirectedLuck + large-scale production by ProBioGen 2020-02-25
Roche–Bicycle Therapeutics: small-molecule drugs, 202002– collab strategic $30m upfront + up to $1.7b r+d of bicycle peptides for cancer Genentech 2020-02-25
Scipio Bioscience–BPCE: investment, 202002 financing round Series A totalling €6m incl existing + co-investor Seventure Partners Quadrivium 1 Fund 2020-02-25
Scipio Bioscience–Financière Arbevel: investment, 202002 financing round Series A totalling €6m incl new + co-investor Financière Arbevel 2020-02-25
Scipio Bioscience–High-Tech Gründerfonds: investment, 202002 financing round Series A totalling €6m incl existing + co-investor HTGF 2020-02-25
Scipio Bioscience–Merck (DE): investment, 202002 financing round Series A totalling €6m incl lead investor M Ventures 2020-02-25
Scipio Bioscience–SEVERAL: investment, 202002 financing round Series A €6m led by M Ventures 2020-02-25
Scipio Bioscience–Verve Capital Partners: investment, 202002 financing round Series A totalling €6m incl new + co-investor investiere 2020-02-25
Glycom–DSM: investment, 202002 acquisition of Glycom A/S by DSM for enterprise value of €765m 2020-02-21
GSK–Immatics: cell therapy, 202002– strategic collab $45m upfront + $1.1b milestones for first two TCR therapeutics programmes + royalties 2020-02-20
BIA Separations–Univ Zagreb: purification technology, 202002– commercial license + collab developm of virus + viral vector immunoaffinity purification 2020-02-19
Servier–Cellectis: T-cell immunotherapy, 202002– collab amendment + expansion ww excl license to develop + commercialise UCARTs tageting CD19 2020-02-18
OMass–SEVERAL: investment, 202002 financing round Series A extension £27.5m bringing total Series A to £41.5m 2020-02-17
Pheno Therapeutics–SEVERAL: investment, 202002– financing round Series A £5m milestone-based over 3 years from Advent Life Sciences + SIB + LifeArc 2020-02-17
Pencil Biosciences–o2h: investment, 202002 investment by o2h Ventures Therapeutics and AI Fund 2020-02-15
Pencil Biosciences–United Kingdom (govt): grant, <202002 received Innovate UK grants 2020-02-15
OncoDNA–Belgium (govt): investment, 202002 financing round Series B totalling €19m incl significant support from co-investor SFPI-FPIM 2020-02-14
OncoDNA–SEVERAL: investment, 202002 financing round Series B €19m co-led by Vesalius Biocapital III + Swisscanto Invest 2020-02-14
OncoDNA–Vesalius Biocapital: investment, 202002 financing round Series B totalling €19m incl co-lead investor Vesalius Biocapital III 2020-02-14
OncoDNA–Zürcher Kantonalbank: investment, 202002 financing round Series B totalling €19m incl co-lead investor Swisscanto Invest by ZKB 2020-02-14
Domainex–Sciad Communications: public relations, 202002 service existent by Sciad 2020-02-13
NanoPin Technologies–Thermo Fisher: mass spectrometry, 202002– collab developm LC-MS-based workflows for blood-based infectious disease diagnostics 2020-02-13
Apexbio/Cycloud–Stilla Technologies: digital PCR technology, 202002 distribution existent in China by Apexbio/Cycloud 2020-02-11
Stilla Technologies–BNP Paribas: investment, 202002 financing round Series B totalling €20m incl existing investor BNP Paribas Développement 2020-02-11
Stilla Technologies–Eurazeo: investment, 202002 financing round Series B totalling €20m incl existing investor Idinvest Partners 2020-02-11
Stilla Technologies–Illumina: investment, 202002 financing round Series B totalling €20m incl existing investor Illumina Ventures 2020-02-11
Stilla Technologies–Kurma: investment, 202002 financing round Series B totalling €20m incl existing investor Kurma Partners 2020-02-11
Stilla Technologies–LBO France: investment, 202002 financing round Series B totalling €20m incl existing investor LBO France 2020-02-11
Stilla Technologies–Paris Saclay Seeds: investment, 202002 financing round Series B totalling €20m incl existing investor Paris Saclay Seed Funds 2020-02-11
1 2 3 ... 101 102 103  next pagenext page



Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top